Moroctocog

Moroctocog is a recombinant factor VIII product used in the treatment of Hemophilia A. It is produced by BioMarin Pharmaceutical and is also known as BMN 270 or Valoctocogene Roxaparvovec.

Overview

Moroctocog, also known as BMN 270 or Valoctocogene Roxaparvovec, is a gene therapy product used in the treatment of Hemophilia A. It is a recombinant factor VIII product, which means it is created using recombinant DNA technology. This involves inserting a copy of the factor VIII gene into a vector, which is then used to produce the factor VIII protein in a laboratory setting.

Mechanism of Action

Moroctocog works by replacing the defective factor VIII gene in patients with Hemophilia A. This allows the body to produce its own factor VIII, a protein that is essential for blood clotting. Without sufficient factor VIII, patients with Hemophilia A are at risk of excessive bleeding and bruising.

Clinical Trials

Moroctocog has undergone several clinical trials to assess its safety and efficacy. In a phase 1/2 trial, patients who received Moroctocog showed a significant reduction in bleeding episodes and a decrease in the need for factor VIII infusions.

Side Effects

As with any medication, Moroctocog can cause side effects. These may include headache, fatigue, joint pain, and changes in liver function. Patients should discuss any concerns with their healthcare provider.

See Also

• Hemophilia A
• Factor VIII
• Gene Therapy
• BioMarin Pharmaceutical

Moroctocog Resources
Latest articles Most recent articles Ongoing trials	Wikipedia